Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Chavez

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
JAMA|August 29, 2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trialAnuoluwapo Osinusi, Eric G Meissner, Yu-Jin Lee, et al.
Lancet (London, England)|January 17, 2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyAnita Kohli, Anuoluwapo Osinusi, Zayani Sims, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
JAMA|August 29, 2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trialAnuoluwapo Osinusi, Eric G Meissner, Yu-Jin Lee, et al.
Lancet (London, England)|January 17, 2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyAnita Kohli, Anuoluwapo Osinusi, Zayani Sims, et al.
Pageof 5